News

Net profit of Epigral declined 6.84% to Rs 80.95 crore in the quarter ended March 2026 as against Rs 86.89 crore during the previous quarter ended March 2025. Sales rose 17.29% to Rs 736.16 crore in the quarter ended March 2026 as against Rs 627.63 crore during the previous quarter ended March 2025.For the full year,net profit declined 7.19% to Rs 331.97 crore in the year ended March 2026 as against Rs 357.69 crore during the previous year ended March 2025. Sales declined 0.90% to Rs 2527.18 crore in the year ended March 2026 as against Rs 2550.13 crore during the previous year ended March 2025. ParticularsQuarter EndedYear EndedMar. 2026Mar. 2025% Var.Mar. 2026Mar. 2025% Var. Sales736.16627.63 17 2527.182550.13 -1 OPM %22.7727.62 -22.4027.87 - PBDT151.23165.28 -9 509.05673.65 -24 PBT109.54131.33 -17 340.76541.09 -37 NP80.9586.89 -7 331.97357.69 -7 Powered by Capital Market - Live News

Epigral announced that the Board of Directors of the Company at its meeting held on 2 May 2026, inter alia, have recommended the final dividend of Rs 5 per equity Share (i.e. 50%) , subject to the approval of the shareholders.

Epigral will hold a meeting of the Board of Directors of the Company on 2 May 2026.

Net profit of Epigral declined 62.26% to Rs 39.11 crore in the quarter ended December 2025 as against Rs 103.63 crore during the previous quarter ended December 2024. Sales declined 7.46% to Rs 597.12 crore in the quarter ended December 2025 as against Rs 645.24 crore during the previous quarter ended December 2024. ParticularsQuarter EndedDec. 2025Dec. 2024% Var. Sales597.12645.24 -7 OPM %17.2028.29 - PBDT97.31186.53 -48 PBT54.56153.62 -64 NP39.11103.63 -62 Powered by Capital Market - Live News

Epigral will hold a meeting of the Board of Directors of the Company on 30 January 2026.Powered by Capital Market - Live News